At a glance
ClinicalIndex Comparison RecordPhase 2Active· 406 enrolled
Drug / intervention
Dasatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase
In Brief
A Phase 2 clinical trial evaluating Dasatinib, Imatinib Mesylate, and 1 other intervention for Chronic Myeloid Leukemia, BCR-ABL1 Positive. Active but no longer recruiting, targeting 406 participants across 340 sites in 2 countries.
Detailed Summary
This randomized phase IIB trial studies imatinib mesylate at two different doses and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia. Imatinib mesylate or dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 2Active
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2003
Enrollment StartAug 2004
Primary CompletionNov 2010
TodayJul 2026
Study CompletionMar 2027
First PostedOct 7, 2003
Enrollment StartAug 15, 2004
Primary CompletionNov 1, 2010
Study CompletionMar 10, 2027
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 22.7 years ago
Interventions
Dasatinibdrug
Given PO
Imatinib Mesylatedrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies